DATA GRAPHICS | Data Byte
GLP-1 boom: no signs of slowing as sales continued to surge in 4Q24
Sales of top brands from both Lilly and Novo recorded all-time highs, again
March 5, 2025 10:41 PM UTC
The GLP-1 market continued to expand in 4Q24, with sales of the top four products, two each from Novo Nordisk and Eli Lilly, reaching new highs.
Diabetes drug Ozempic semaglutide from Novo Nordisk A/S (CSE:NOVO B; NYSE:NVO) maintained both its lead position and upward growth trajectory. The once-weekly subcutaneous therapy has brought in over $4 billion in sales in each of the last five quarters. Its annual sales grew 25% last year, to over $17 billion. ...